Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan, fludarabine, and low-dose TBI for pediatric AML/MDS HCT
NCT01772953Phase 2Completed
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- Sep 2013
- Primary completion
- Aug 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Center for International Blood and Marrow Transplant Research. Started Sep 2013; status: completed.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01772953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01772953.